Generic Name and Formulations:
Dinoprostone 10mg; controlled-release vaginal insert w. retrieval system.
Indications for CERVIDIL:
Cervical ripening in patients at or near term when there is an indication for labor induction.
Fetal distress where delivery is not imminent. Unexplained vaginal bleeding. Presence or suspicion of cephalopelvic disproportion. Where oxytocics or prolonged uterine contractions are inappropriate, including previous cesarean section, major uterine surgery. Multipara with ≥6 previous term pregnancies. Concomitant oxytocics. Remove insert if uterine hyperstimulation, labor, sustained uterine contractions, or other fetal/maternal adverse reactions occur and prior to amniotomy.
For hospital use when appropriate obstetric care is present. Ruptured membranes. Non-vertex, non-singleton presentation. Previous uterine hypertony. Glaucoma. History of childhood asthma. Monitor uterine activity, fetal status, cervical dilatation/effacement. Pregnancy (Cat.C).
Potentiates oxytocics; delay administration of oxytocics at least 30 minutes after removal of insert.
Uterine hyperstimulation, fetal distress.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a